Cannabis-Related Disorders and Toxic Effects
NEJM 389: 2267-2275, Gorelick,D.A., 2023
Neuroimaging Biomarkers in a Patient with Probable Psychiatric-Onset Prodromal Dementia with Lewy Bodies
Neurol 99:654-657, Urso, D.,et al, 2022
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Muscular Dystrophies
Lancet 394:2025-2038, Mercuri, E.,et al, 2019
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Migraine
NEJM 377:553-561, Charles, A., 2017
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Synthetic Cannabinoid-Related Illnesses and Deaths
NEJM 373:103-107, Trecki, J.,et al, 2015
Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014
Progressive Weakness with Respiratory Failure in a Patient with Sarcoidosis
Arch Neurol 69:534-537, Chaudhry,P.,et al, 2012
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Suicide-Related Events in Patients Treated With Antiepileptic Drugs
NEJM 363:542-551, Arana,A., et al, 2010
Polymyalgia Rheumatica
BMJ 336:765-769, Michet,C.J. &Matteson,E.L., 2008
Quetiapine for Agitation or Psychosis in Patients with Dementia and Parkinsonism
Neurol 68:1356-1363, Kurlan,R.,et al, 2007
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimers Disease
NEJM 355:1525-1538,1604, Schneider,L.S.,et al, 2006
Psychotropic Effects of Antiepileptic Drugs
Neurol 67:1916-1925, Ettinger,A.B., 2006
Psychosis Related to Ropinirole
Am J Psychiatry 163:546-547, Perea,E.,et al, 2006
Respiratory Adverse Events Associated with Diazepam Rectal Gel
Neurol 64:1768-1770, Pellock,J.M. &Shinnar,S., 2005
Ten Most Commonly Asked Questions About the Psychiatric Aspects of Parkinson's Disease
The Neurologist 9:50-56, Reich,S.G. & Marsh,L., 2003
Quetiapine for L-Dopa-Induced Psychosis in PD
Neurol 54:1538, Weiner,W.J.,et al, 2000
Serotonin Sydrome
Medicine 79:201-209, Mason,P.J. et al, 2000
Treatment of Drug-Induced Psychosis with Quetiapine and Clozapine in Parkinson's Disease
Neurol 55:1753-1754, Dewey,R.B.Jr. & O'Suilleabhain,P.E., 2000
Central Anticholinergic Syndrome on Therapeutic Doses of Cyproheptadine
Pediatrics 103:158-160, Watemberg,N.M.,et al, 1999
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
NEJM 340:757-763,801, The Parkinson Study Group, 1999
Transderm-induced Psychosis in Parkinson's Disease
Neurol 53:433-434, Minagar,A.,et al, 1999
Diagnosing Dementia with Lewy Bodies
Lancet 354:1227-1228, McKeith,I.G.,et al, 1999
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Psychiatric Adverse Events During Vigabatrin Therapy
Neurol 53:1503-1511, Levinson,D.F.&Devinsky,O., 1999
Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 50:1195-1196, Wolters,E.C.,et al, 1998
Complications of Sedation with Midazolam in the Intensive Care Unit and a Comparison with Other Sedative Regimens
Crit Care Med 26:947-956, Shafer,A., 1998
Coma Induced by Abuse of Gamma-Hydroxybutyrate (GBH or Liquid Ecstasy) :A Case Report
BMJ 314:35-36, Thomas,G.,et al, 1997
Olanzapine:A Novel Atypical Neuroleptic Agent
Lancet 349:1264-1265, Reus,V.I., 1997
Managing the Late Complications of Parkinson's Disease
Neurol 49:549-557, Waters,C.H., 1997
A Survey of Antidepressant Drug Use in Parkinson's Disease
Neurol 49:1168-1170, Richard,I.H.,et al, 1997
Side Effect Profile of Interferon Beta-1b in MS:Results of an Open Label Trial
Neurol 46:552-554, Neilley,L.K.,et al, 1996
Ganciclovir-Induced Psychosis
NEJM 335:1937, Hansen,B.A.,et al, 1996
Post-Malaria Neurological syndrome
Lancet 348:917-921, Mai,N.T.H.,et al, 1996
A Depressed Workman with Heatstroke
Lancet 347:1016, Albukrek,D.,et al, 1996
Management of the Behavioral Manifestations of Dementia
Arch Int Med 155:250-260, Yeager,B.F.,et al, 1995
Low-Dose Clozapine in the Treatment of Levodopa-Induced Mental Disturbances in Parkinson's Disease
Neurol 45:432-434, Rabey,J.M.,et al, 1995
Neurotoxicity in Liver Transplant Recipients with Cyclosporine Immunosuppression
Neurol 45:1962-1964, Wijdicks,E.F.M.,et al, 1995
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Effects of Vigabatrin on Partial Seizures and Cognitive Function
JNNP 57:1057-1063, Grunewald,R.A.,et al, 1994
Epileptic Seizures in Patients with Acute Catatonic Syndrome
JNNP 57:1419-1422, Primavera,A.,et al, 1994
Increase of Parkinson Disability after Fluoxetine Medication
Neurol 43:211-213, Steur,E.N.H.J., 1993
Side Effects of Glucocorticoid Treatment, Experience of the Optic Neuritis Treatment Trial
JAMA 269:2110-2112, Chrousos,G.A.,et al, 1993
Missed Neuroleptic Malignant Syndrome
BMJ 304:831-832, Renwick,D.S.,et al, 1992
Prolonged Weakness after Long-Term Infusion of Vecuronium Bromide
Ann Int Med 117:484-486, Kupfer,Y.,et al, 1992